INS and type 2 diabetes mellitus: ORMD-0801 [162], an oral insulin hypoglycemic capsule containing soybean trypsin inhibitor and permeation enhancers (ethylenediaminetetraacetic acid and bile salts) [38], has shown positive Phase II clinical results for the treatment of T2DM [163].